Art

J-GLOBAL ID：201902201018366171   Reference number：19S1743991

Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors

Author (11)： Eskens, Ferry A. L. M. (Department of Medical Oncology, Erasmus University Medical Center) ,  De Jonge, Maja J. A. (Department of Medical Oncology, Erasmus University Medical Center) ,  Burger, Herman (Department of Medical Oncology, Erasmus University Medical Center) ,  Van Doorn, Leni (Department of Medical Oncology, Erasmus University Medical Center) ,  Verweij, Jaap (Department of Medical Oncology, Erasmus University Medical Center) ,  Thomeer, Maarten (Department of Radiology, Erasmus University Medical Center) ,  Bhargava, Pankaj (AVEO Pharmaceuticals, Inc.) ,  Cotreau, Monette M. (AVEO Pharmaceuticals, Inc.) ,  Esteves, Brooke (AVEO Pharmaceuticals, Inc.) ,  Isoe, Toshiyuki (Kyowa Hakko Kirin Co Ltd.) ,  Hayashi, Kunihiko (Kyowa Hakko Kirin Co Ltd.)
Material： Clinical Cancer Research
Volume： 17  Issue： 22  Page： 7156-7163  Publication year： 2011 
JST Material Number： SCOPUS  ISSN： 1078-0432  CODEN： CCREF 
Country of issue： United States (USA)  Language： English (EN)

Terms in the title (1)： VEGF